Evolution and expansion of multidrug-resistant malaria in southeast Asia: a genomic epidemiology study.


Journal

The Lancet. Infectious diseases
ISSN: 1474-4457
Titre abrégé: Lancet Infect Dis
Pays: United States
ID NLM: 101130150

Informations de publication

Date de publication:
09 2019
Historique:
received: 11 05 2019
revised: 15 06 2019
accepted: 20 06 2019
pubmed: 28 7 2019
medline: 13 6 2020
entrez: 27 7 2019
Statut: ppublish

Résumé

A multidrug-resistant co-lineage of Plasmodium falciparum malaria, named KEL1/PLA1, spread across Cambodia in 2008-13, causing high rates of treatment failure with the frontline combination therapy dihydroartemisinin-piperaquine. Here, we report on the evolution and spread of KEL1/PLA1 in subsequent years. For this genomic epidemiology study, we analysed whole genome sequencing data from P falciparum clinical samples collected from patients with malaria between 2007 and 2018 from Cambodia, Laos, northeastern Thailand, and Vietnam, through the MalariaGEN P falciparum Community Project. Previously unpublished samples were provided by two large-scale multisite projects: the Tracking Artemisinin Resistance Collaboration II (TRAC2) and the Genetic Reconnaissance in the Greater Mekong Subregion (GenRe-Mekong) project. By investigating genome-wide relatedness between parasites, we inferred patterns of shared ancestry in the KEL1/PLA1 population. We analysed 1673 whole genome sequences that passed quality filters, and determined KEL1/PLA1 status in 1615. Before 2009, KEL1/PLA1 was only found in western Cambodia; by 2016-17 its prevalence had risen to higher than 50% in all of the surveyed countries except for Laos. In northeastern Thailand and Vietnam, KEL1/PLA1 exceeded 80% of the most recent P falciparum parasites. KEL1/PLA1 parasites maintained high genetic relatedness and low diversity, reflecting a recent common origin. Several subgroups of highly related parasites have recently emerged within this co-lineage, with diverse geographical distributions. The three largest of these subgroups (n=84, n=79, and n=47) mostly emerged since 2016 and were all present in Cambodia, Laos, and Vietnam. These expanding subgroups carried new mutations in the crt gene, which arose on a specific genetic background comprising multiple genomic regions. Four newly emerging crt mutations were rare in the early period and became more prevalent by 2016-17 (Thr93Ser, rising to 19·8%; His97Tyr to 11·2%; Phe145Ile to 5·5%; and Ile218Phe to 11·1%). After emerging and circulating for several years within Cambodia, the P falciparum KEL1/PLA1 co-lineage diversified into multiple subgroups and acquired new genetic features, including novel crt mutations. These subgroups have rapidly spread into neighbouring countries, suggesting enhanced fitness. These findings highlight the urgent need for elimination of this increasingly drug-resistant parasite co-lineage, and the importance of genetic surveillance in accelerating malaria elimination efforts. Wellcome Trust, Bill & Melinda Gates Foundation, UK Medical Research Council, and UK Department for International Development.

Sections du résumé

BACKGROUND
A multidrug-resistant co-lineage of Plasmodium falciparum malaria, named KEL1/PLA1, spread across Cambodia in 2008-13, causing high rates of treatment failure with the frontline combination therapy dihydroartemisinin-piperaquine. Here, we report on the evolution and spread of KEL1/PLA1 in subsequent years.
METHODS
For this genomic epidemiology study, we analysed whole genome sequencing data from P falciparum clinical samples collected from patients with malaria between 2007 and 2018 from Cambodia, Laos, northeastern Thailand, and Vietnam, through the MalariaGEN P falciparum Community Project. Previously unpublished samples were provided by two large-scale multisite projects: the Tracking Artemisinin Resistance Collaboration II (TRAC2) and the Genetic Reconnaissance in the Greater Mekong Subregion (GenRe-Mekong) project. By investigating genome-wide relatedness between parasites, we inferred patterns of shared ancestry in the KEL1/PLA1 population.
FINDINGS
We analysed 1673 whole genome sequences that passed quality filters, and determined KEL1/PLA1 status in 1615. Before 2009, KEL1/PLA1 was only found in western Cambodia; by 2016-17 its prevalence had risen to higher than 50% in all of the surveyed countries except for Laos. In northeastern Thailand and Vietnam, KEL1/PLA1 exceeded 80% of the most recent P falciparum parasites. KEL1/PLA1 parasites maintained high genetic relatedness and low diversity, reflecting a recent common origin. Several subgroups of highly related parasites have recently emerged within this co-lineage, with diverse geographical distributions. The three largest of these subgroups (n=84, n=79, and n=47) mostly emerged since 2016 and were all present in Cambodia, Laos, and Vietnam. These expanding subgroups carried new mutations in the crt gene, which arose on a specific genetic background comprising multiple genomic regions. Four newly emerging crt mutations were rare in the early period and became more prevalent by 2016-17 (Thr93Ser, rising to 19·8%; His97Tyr to 11·2%; Phe145Ile to 5·5%; and Ile218Phe to 11·1%).
INTERPRETATION
After emerging and circulating for several years within Cambodia, the P falciparum KEL1/PLA1 co-lineage diversified into multiple subgroups and acquired new genetic features, including novel crt mutations. These subgroups have rapidly spread into neighbouring countries, suggesting enhanced fitness. These findings highlight the urgent need for elimination of this increasingly drug-resistant parasite co-lineage, and the importance of genetic surveillance in accelerating malaria elimination efforts.
FUNDING
Wellcome Trust, Bill & Melinda Gates Foundation, UK Medical Research Council, and UK Department for International Development.

Identifiants

pubmed: 31345709
pii: S1473-3099(19)30392-5
doi: 10.1016/S1473-3099(19)30392-5
pmc: PMC6715858
pii:
doi:

Substances chimiques

Antimalarials 0
Artemisinins 0
Membrane Transport Proteins 0
PfCRT protein, Plasmodium falciparum 0
Protozoan Proteins 0
Quinolines 0
artenimol 6A9O50735X
piperaquine A0HV2Q956Y

Types de publication

Journal Article Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

943-951

Subventions

Organisme : Wellcome Trust
ID : 203141
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0600718
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 206194
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 098051
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 090770
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/M006212/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 204911
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 204911/Z/16/Z
Pays : United Kingdom

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.

Références

Parasitol Int. 2009 Sep;58(3):201-9
pubmed: 19393762
N Engl J Med. 2009 Jul 30;361(5):455-67
pubmed: 19641202
Lancet. 2012 May 26;379(9830):1960-6
pubmed: 22484134
Nature. 2012 Jul 19;487(7407):375-9
pubmed: 22722859
Lancet Infect Dis. 2012 Nov;12(11):851-8
pubmed: 22940027
Antimicrob Agents Chemother. 2013 Feb;57(2):818-26
pubmed: 23208711
Nat Genet. 2013 Jun;45(6):648-55
pubmed: 23624527
Nature. 2014 Jan 2;505(7481):50-5
pubmed: 24352242
Proc Natl Acad Sci U S A. 2014 Apr 29;111(17):E1759-67
pubmed: 24728833
N Engl J Med. 2014 Jul 31;371(5):411-23
pubmed: 25075834
Nat Genet. 2015 Mar;47(3):226-34
pubmed: 25599401
Nature. 2015 Oct 8;526(7572):207-211
pubmed: 26375008
Lancet Infect Dis. 2016 Mar;16(3):357-65
pubmed: 26774243
Elife. 2016 Mar 04;5:null
pubmed: 26943619
Lancet Infect Dis. 2017 Feb;17(2):164-173
pubmed: 27818095
Lancet Infect Dis. 2017 Feb;17(2):174-183
pubmed: 27818097
Malar J. 2016 Dec 20;15(1):597
pubmed: 27998271
Malar J. 2017 Jan 13;16(1):27
pubmed: 28086775
Lancet Infect Dis. 2017 May;17(5):491-497
pubmed: 28161569
Emerg Infect Dis. 2017 Apr;23(4):715-717
pubmed: 28322709
MBio. 2017 May 9;8(3):
pubmed: 28487425
J Infect Dis. 2017 Aug 15;216(4):468-476
pubmed: 28931241
Lancet Infect Dis. 2017 Oct;17(10):1022-1023
pubmed: 28948924
Lancet Infect Dis. 2018 Mar;18(3):337-345
pubmed: 29398391
Antimicrob Agents Chemother. 2018 Mar 27;62(4):
pubmed: 29439977
Nat Commun. 2018 May 2;9(1):1769
pubmed: 29720620
Nat Commun. 2018 Aug 17;9(1):3314
pubmed: 30115924
Lancet Infect Dis. 2019 Sep;19(9):952-961
pubmed: 31345710

Auteurs

William L Hamilton (WL)

Wellcome Sanger Institute, Hinxton, UK; Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

Roberto Amato (R)

Wellcome Sanger Institute, Hinxton, UK; MRC Centre for Genomics and Global Health, Big Data Institute, University of Oxford, Oxford, UK.

Rob W van der Pluijm (RW)

Mahidol-Oxford Tropical Medicine Research Unit, Mahidol University, Bangkok, Thailand; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Christopher G Jacob (CG)

Wellcome Sanger Institute, Hinxton, UK.

Huynh Hong Quang (HH)

Institute of Malariology, Parasitology and Entomology, Quy Nhon, Vietnam.

Nguyen Thanh Thuy-Nhien (NT)

Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam.

Tran Tinh Hien (TT)

Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam.

Bouasy Hongvanthong (B)

Centre of Malariology, Parasitology, and Entomology, Vientiane, Laos.

Keobouphaphone Chindavongsa (K)

Centre of Malariology, Parasitology, and Entomology, Vientiane, Laos.

Mayfong Mayxay (M)

Institute of Research and Education Development, University of Health Sciences, Vientiane, Laos; Lao-Oxford-Mahosot Hospital Wellcome Trust Research Unit (LOMWRU), Vientiane, Laos.

Rekol Huy (R)

National Center for Parasitology, Entomology, and Malaria Control, Phnom Penh, Cambodia.

Rithea Leang (R)

National Center for Parasitology, Entomology, and Malaria Control, Phnom Penh, Cambodia.

Cheah Huch (C)

National Center for Parasitology, Entomology, and Malaria Control, Phnom Penh, Cambodia.

Lek Dysoley (L)

National Center for Parasitology, Entomology, and Malaria Control, Phnom Penh, Cambodia.

Chanaki Amaratunga (C)

Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA.

Seila Suon (S)

National Center for Parasitology, Entomology, and Malaria Control, Phnom Penh, Cambodia.

Rick M Fairhurst (RM)

Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA.

Rupam Tripura (R)

Mahidol-Oxford Tropical Medicine Research Unit, Mahidol University, Bangkok, Thailand; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Thomas J Peto (TJ)

Mahidol-Oxford Tropical Medicine Research Unit, Mahidol University, Bangkok, Thailand; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Yok Sovann (Y)

Provincial Health Department, Pailin, Cambodia.

Podjanee Jittamala (P)

Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.

Borimas Hanboonkunupakarn (B)

Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.

Sasithon Pukrittayakamee (S)

Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; The Royal Society of Thailand, Bangkok, Thailand.

Nguyen Hoang Chau (NH)

Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam.

Mallika Imwong (M)

Mahidol-Oxford Tropical Medicine Research Unit, Mahidol University, Bangkok, Thailand; Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.

Mehul Dhorda (M)

Mahidol-Oxford Tropical Medicine Research Unit, Mahidol University, Bangkok, Thailand; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Worldwide Antimalarial Resistance Network (WWARN), Asia Regional Centre, Bangkok, Thailand.

Ranitha Vongpromek (R)

Mahidol-Oxford Tropical Medicine Research Unit, Mahidol University, Bangkok, Thailand; Worldwide Antimalarial Resistance Network (WWARN), Asia Regional Centre, Bangkok, Thailand.

Xin Hui S Chan (XHS)

Mahidol-Oxford Tropical Medicine Research Unit, Mahidol University, Bangkok, Thailand; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Richard J Maude (RJ)

Mahidol-Oxford Tropical Medicine Research Unit, Mahidol University, Bangkok, Thailand; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Harvard TH Chan School of Public Health, Harvard University, Boston, MA, USA.

Richard D Pearson (RD)

Wellcome Sanger Institute, Hinxton, UK; MRC Centre for Genomics and Global Health, Big Data Institute, University of Oxford, Oxford, UK.

T Nguyen (T)

Wellcome Sanger Institute, Hinxton, UK.

Kirk Rockett (K)

Wellcome Sanger Institute, Hinxton, UK; Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK.

Eleanor Drury (E)

Wellcome Sanger Institute, Hinxton, UK.

Sónia Gonçalves (S)

Wellcome Sanger Institute, Hinxton, UK.

Nicholas J White (NJ)

Mahidol-Oxford Tropical Medicine Research Unit, Mahidol University, Bangkok, Thailand; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Nicholas P Day (NP)

Mahidol-Oxford Tropical Medicine Research Unit, Mahidol University, Bangkok, Thailand; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Dominic P Kwiatkowski (DP)

Wellcome Sanger Institute, Hinxton, UK; MRC Centre for Genomics and Global Health, Big Data Institute, University of Oxford, Oxford, UK. Electronic address: dominic@sanger.ac.uk.

Arjen M Dondorp (AM)

Mahidol-Oxford Tropical Medicine Research Unit, Mahidol University, Bangkok, Thailand; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Olivo Miotto (O)

Wellcome Sanger Institute, Hinxton, UK; MRC Centre for Genomics and Global Health, Big Data Institute, University of Oxford, Oxford, UK; Mahidol-Oxford Tropical Medicine Research Unit, Mahidol University, Bangkok, Thailand; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK. Electronic address: olivo@tropmedres.ac.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH